# Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy

> **NCT01538680** · — · NO_LONGER_AVAILABLE · sponsor: **Bayer**

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** Regorafenib (BAY73-4506)

## Key facts

- **NCT ID:** NCT01538680
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2019-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01538680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01538680, "Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT01538680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*